Drug intelligence / Profile preview

Ad5CMV-p53

Development stage: Phase 2
Lead developer: Introgen Therapeutics
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intratumoral, Intravenous

Overview

Ad5CMV-p53 is a replication-impaired adenoviral vector carrying the wild-type p53 gene. It functions by delivering the p53 tumor suppressor gene to cancer cells, where the expressed p53 protein mediates cell-cycle arrest, DNA repair, or induces apoptosis, senescence, and/or autophagy depending on cellular stress conditions. The p53 gene is frequently mutated in human tumors, and replacing this gene via adenovirally-mediated gene therapy aims to restore normal p53 function and increase apoptosis in cancer cells.

Brand names: Advexin
Other names: contusugene ladenovecadenoviral p53 gene therapy

Targets

TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on Ad5CMV-p53.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad5CMV-p53.

Explore the full profile